0001818794false00018187942024-05-222024-05-22

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 22, 2024

 

Dyne Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

001-39509

36-4883909

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

 

 

1560 Trapelo Road

Waltham, Massachusetts

 

02451

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (781) 786-8230

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common stock, $0.0001 par value per share

DYN

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

Dyne Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders on May 22, 2024. The following is a summary of the matters voted on at that meeting.

a)
The stockholders of the Company elected Carlo Incerti, M.D., Catherine Stehman-Breen, M.D. and John G. Cox as Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified. The results of the stockholders’ vote with respect to such matter were as follows:

 

Name

 

For

 

Withheld

 

Broker Non-Votes

Carlo Incerti, M.D.

 

61,028,245

 

8,752,856

 

5,235,919

Catherine Stehman-Breen, M.D.

 

55,026,485

 

14,325,362

 

5,665,173

John G. Cox

 

69,763,860

 

32,767

 

5,220,393

 

b)
The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders’ vote with respect to such matter were as follows:

 

For

 

Against

 

Abstain

74,962,217

 

12,377

 

42,426

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

DYNE THERAPEUTICS, INC.

 

 

 

Date: May 24, 2024

By:

/s/ John G. Cox

 

 

Name:

John G. Cox

 

 

Title:

President and Chief Executive Officer

 

 

v3.24.1.1.u2
Document and Entity Information
May 22, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 22, 2024
Entity Registrant Name Dyne Therapeutics, Inc.
Entity Central Index Key 0001818794
Entity Incorporation, State or Country Code DE
Entity File Number 001-39509
Entity Tax Identification Number 36-4883909
Entity Address, Address Line One 1560 Trapelo Road
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code 781
Local Phone Number 786-8230
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.0001 par value per share
Trading Symbol DYN
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Dyne Therapeutics Charts.
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Dyne Therapeutics Charts.